GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jinhe Biotechnology Co Ltd (SZSE:002688) » Definitions » Capex-to-Operating-Cash-Flow

Jinhe Biotechnology Co (SZSE:002688) Capex-to-Operating-Cash-Flow : 1.14 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Jinhe Biotechnology Co Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Jinhe Biotechnology Co's Capital Expenditure for the three months ended in Mar. 2024 was ¥-83.92 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was ¥73.39 Mil.

Hence, Jinhe Biotechnology Co's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2024 was 1.14.


Jinhe Biotechnology Co Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Jinhe Biotechnology Co's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jinhe Biotechnology Co Capex-to-Operating-Cash-Flow Chart

Jinhe Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.79 2.51 3.23 2.30

Jinhe Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.74 2.93 2.73 1.14

Competitive Comparison of Jinhe Biotechnology Co's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Jinhe Biotechnology Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jinhe Biotechnology Co's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jinhe Biotechnology Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Jinhe Biotechnology Co's Capex-to-Operating-Cash-Flow falls into.



Jinhe Biotechnology Co Capex-to-Operating-Cash-Flow Calculation

Jinhe Biotechnology Co's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-457.217) / 198.766
=2.30

Jinhe Biotechnology Co's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-83.919) / 73.39
=1.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jinhe Biotechnology Co  (SZSE:002688) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Jinhe Biotechnology Co Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Jinhe Biotechnology Co's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Jinhe Biotechnology Co (SZSE:002688) Business Description

Traded in Other Exchanges
N/A
Address
Zone B3 Xinghai Plaza, 1-7-2 Building 27, Shahekou District, Dalian, CHN, 116023
Jinhe Biotechnology Co Ltd is engaged in manufacturing veterinary feed additives, veterinary vaccines, veterinary chemicals, corn starch processing and industrial wastewater treatment business.
Executives
Wang Zhi Jun Directors, executives
Liu Ying Chun Executives
Deng Yi Xin Secretary Dong
Li Fu Zhong Director
Liu Yun Tian Directors, executives
Xie Chang Xian Directors, executives
Wang Dong Xiao Director
Yao Jian Xiong Supervisors
Zheng Liu Ji Supervisors
Niu You Shan Executives
Wu Ming Xia Director
Li Wei Qi Directors, executives
Wu Rui Gang Executives

Jinhe Biotechnology Co (SZSE:002688) Headlines

No Headlines